pf-07265807

PF-07265807 is a selective small-molecule inhibitor of the receptor tyrosine kinases MERTK (Mer proto-oncogene, tyrosine kinase) and AXL. These kinases are part of the tumor-associated macrophage kinase (TAMK) family and play roles in immune homeostasis and cancer progression. Inhibition of MERTK and AXL by PF-07265807 is designed to lower the threshold for immune activation, thereby promoting antitumor immunity. Preclinical studies demonstrated that PF-07265807 has antitumor activity both as monotherapy and in combination with anti-programmed cell death protein 1 (anti-PD-1) antibodies. The drug was developed by Pfizer for use in advanced or metastatic solid tumors but its clinical development was discontinued after phase 1 trials[2][4][5][6][8].